488 results on '"luminal breast cancer"'
Search Results
2. A comprehensive molecular characterization of a claudin-low luminal B breast tumor.
- Author
-
Giovannini, Sara, Smirnov, Artem, Concetti, Livia, Scimeca, Manuel, Mauriello, Alessandro, Bischof, Julia, Rovella, Valentina, Melino, Gerry, Buonomo, Claudio Oreste, Candi, Eleonora, and Bernassola, Francesca
- Subjects
- *
APOLIPOPROTEIN B , *RNA editing , *ESTROGEN receptors , *BREAST tumors , *BREAST cancer - Abstract
Breast cancer is the most common cause of death from cancer in women. Here, we present the case of a 43-year-old woman, who received a diagnosis of claudin-low luminal B breast cancer. The lesion revealed to be a poorly differentiated high-grade infiltrating ductal carcinoma, which was strongly estrogen receptor (ER)/progesterone receptor (PR) positive and human epidermal growth factor receptor (HER2) negative. Her tumor underwent in-depth chromosomal, mutational and gene expression analyses. We found a pathogenic protein truncating mutation in the TP53 gene, which is predicted to disrupt its transcriptional activity. The patient also harbors germline mutations in some mismatch repair (MMR) genes, and her tumor displays the presence of immune infiltrates, high tumor mutational burden (TMB) status and the apolipoprotein B mRNA editing enzyme catalytic polypeptide 3 (APOBEC3) associated signatures, which, overall, are predictive for the use of immunotherapy. Here, we propose promising prognostic indicators as well as potential therapeutic strategies based on the molecular characterization of the tumor. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
3. Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study.
- Author
-
Püsküllüoğlu, Miroslawa, Ziobro, Marek, Lompart, Joanna, Rudzińska, Agnieszka, Zemełka, Tomasz, Jaworska, Justyna, Ochenduszko, Sebastian, and Grela-Wojewoda, Aleksandra
- Subjects
- *
PROTEIN kinase inhibitors , *DRUG side effects , *BREAST tumors , *ANTINEOPLASTIC agents , *TERMINATION of treatment , *DRUG therapy , *TREATMENT effectiveness , *CANCER patients , *AGE distribution , *TUMOR grading , *TUMOR markers , *RETROSPECTIVE studies , *CANCER chemotherapy , *LONGITUDINAL method , *ADJUVANT chemotherapy , *METASTASIS , *STATISTICS , *PROGRESSION-free survival , *CYCLIN-dependent kinases , *TIME , *OVERALL survival - Abstract
Simple Summary: This study investigated one of the treatment options for advanced breast cancer patients after they completed standard therapy that combines hormone therapy and specific targeted agents called cyclin-dependent kinase 4/6 inhibitors. We wanted to understand why in real-world patients start chemotherapy after finishing standard initial treatment, how they respond to it, and what factors might affect their outcomes. We found that chemotherapy was often used when patients faced dissemination to internal organs with the risk of further progression, but it provided limited benefits. We suggest that modern drugs recommended by guidelines before chemotherapy should be better reimbursed in Poland. This research could help doctors make better treatment decisions and improve future clinical trials. The standard therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer includes the use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapy. The optimal post-CDK4/6i treatment sequence is unclear. This cohort study evaluated the initiation, characteristics, and outcomes of chemotherapy following CDK4/6i-based treatment. Among the 227 patients who began CDK4/6i therapy, 114 completed it. Seventy-nine female patients received further treatment, including 55 receiving chemotherapy. The average age was 60.1 years. Post-CDK4/6i chemotherapy was typically (69.1%) first-line due to an impending visceral crisis. The median progression-free survival (mPFS) was 3.0 months (range 0.5–18.9), and the median overall survival (mOS) was 8.3 months (0.5–26.1). The median OS from the end of CDK4/6i treatment was 12.4 months (1.5–26.8). In univariate analysis, neither mPFS nor mOS was associated with age, tumor grade, receptor status, Ki67 status, time from diagnosis to CDK4/6i cessation, therapy line, or CDK4/6i type. Dose reduction occurred in 12 patients (21.8%), and chemotherapy was ceased due to adverse events in 8 patients (14.6%). Chemotherapy showed limited benefit regardless of the regimen. The role of chemotherapy may evolve with broader CDK4/6i use in adjuvant treatment. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
4. A comprehensive molecular characterization of a claudin-low luminal B breast tumor
- Author
-
Sara Giovannini, Artem Smirnov, Livia Concetti, Manuel Scimeca, Alessandro Mauriello, Julia Bischof, Valentina Rovella, Gerry Melino, Claudio Oreste Buonomo, Eleonora Candi, and Francesca Bernassola
- Subjects
Luminal breast cancer ,Claudin‐low tumors ,Biology (General) ,QH301-705.5 - Abstract
Abstract Breast cancer is the most common cause of death from cancer in women. Here, we present the case of a 43-year-old woman, who received a diagnosis of claudin-low luminal B breast cancer. The lesion revealed to be a poorly differentiated high-grade infiltrating ductal carcinoma, which was strongly estrogen receptor (ER)/progesterone receptor (PR) positive and human epidermal growth factor receptor (HER2) negative. Her tumor underwent in-depth chromosomal, mutational and gene expression analyses. We found a pathogenic protein truncating mutation in the TP53 gene, which is predicted to disrupt its transcriptional activity. The patient also harbors germline mutations in some mismatch repair (MMR) genes, and her tumor displays the presence of immune infiltrates, high tumor mutational burden (TMB) status and the apolipoprotein B mRNA editing enzyme catalytic polypeptide 3 (APOBEC3) associated signatures, which, overall, are predictive for the use of immunotherapy. Here, we propose promising prognostic indicators as well as potential therapeutic strategies based on the molecular characterization of the tumor.
- Published
- 2024
- Full Text
- View/download PDF
5. Left homonymous hemianopia as an atypical manifestation of isolated pachymeningeal metastasis secondary to breast cancer: Case report and review of the literature
- Author
-
Aziz Ahizoune, MD, Moad Belouad, MD, Houda Alloussi, MD, Mohamed Allaoui, MD, Mohamed Hamid, MD, and Ahmed Bourazza, MD
- Subjects
Dural metastasis ,Breast cancer ,Homonymous hemianopia ,Luminal breast cancer ,Isolated pachymeningeal metastasis ,Carcinomatous meningitis ,Medical physics. Medical radiology. Nuclear medicine ,R895-920 - Abstract
Breast cancer is the most frequently diagnosed cancer in women and is caused by the uncontrolled proliferation of breast cells. Metastases from breast cancer to the central nervous system have been described frequently in the literature, but dural metastases without cerebral parenchymal involvement are rarely reported. The latter condition is known as isolated pachymeningeal metastasis (IPM). Herein, we report the case of a 52-year-old female patient who presented left homonymous hemianopia secondary to a right occipital lobe injury which was compressed by a dural thickening identified on brain MRI. Etiological investigations revealed suspicious breast lesions on chest CT scan. Anatomopathological examination of these lesions was consistent with luminal breast cancer. The diagnosis of IPM following breast cancer was confirmed, and the patient underwent chemotherapy treatment.
- Published
- 2024
- Full Text
- View/download PDF
6. FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugs
- Author
-
Monika Gorska-Arcisz, Marta Popeda, Marcin Braun, Dominika Piasecka, Joanna I. Nowak, Kamila Kitowska, Grzegorz Stasilojc, Marcin Okroj, Hanna M. Romanska, and Rafal Sadej
- Subjects
FGFR2 ,Autophagy ,p62 ,Keap1 ,Nrf-2 ,Luminal breast cancer ,Cytology ,QH573-671 - Abstract
Abstract Background Genetic abnormalities in the FGFR signalling occur in 40% of breast cancer (BCa) patients resistant to anti-ER therapy, which emphasizes the potential of FGFR-targeting strategies. Recent findings indicate that not only mutated FGFR is a driver of tumour progression but co-mutational landscapes and other markers should be also investigated. Autophagy has been recognized as one of the major mechanisms underlying the role of tumour microenvironment in promotion of cancer cell survival, and resistance to anti-ER drugs. The selective autophagy receptor p62/SQSTM1 promotes Nrf-2 activation by Keap1/Nrf-2 complex dissociation. Herein, we have analysed whether the negative effect of FGFR2 on BCa cell response to anti-ER treatment involves the autophagy process and/or p62/Keap1/Nrf-2 axis. Methods The activity of autophagy in ER-positive MCF7 and T47D BCa cell lines was determined by analysis of expression level of autophagy markers (p62 and LC3B) and monitoring of autophagosomes’ maturation. Western blot, qPCR and proximity ligation assay were used to determine the Keap1/Nrf-2 interaction and Nrf-2 activation. Analysis of 3D cell growth in Matrigel® was used to assess BCa cell response to applied treatments. In silico gene expression analysis was performed to determine FGFR2/Nrf-2 prognostic value. Results We have found that FGFR2 signalling induced autophagy in AMPKα/ULK1-dependent manner. FGFR2 activity promoted dissociation of Keap1/Nrf-2 complex and activation of Nrf-2. Both, FGFR2-dependent autophagy and activation of Nrf-2 were found to counteract the effect of anti-ER drugs on BCa cell growth. Moreover, in silico analysis showed that high expression of NFE2L2 (gene encoding Nrf-2) combined with high FGFR2 expression was associated with poor relapse-free survival (RFS) of ER+ BCa patients. Conclusions This study revealed the unknown role of FGFR2 signalling in activation of autophagy and regulation of the p62/Keap1/Nrf-2 interdependence, which has a negative impact on the response of ER+ BCa cells to anti-ER therapies. The data from in silico analyses suggest that expression of Nrf-2 could act as a marker indicating potential benefits of implementation of anti-FGFR therapy in patients with ER+ BCa, in particular, when used in combination with anti-ER drugs. Graphical Abstract
- Published
- 2024
- Full Text
- View/download PDF
7. FGFR2-triggered autophagy and activation of Nrf-2 reduce breast cancer cell response to anti-ER drugs.
- Author
-
Gorska-Arcisz, Monika, Popeda, Marta, Braun, Marcin, Piasecka, Dominika, Nowak, Joanna I., Kitowska, Kamila, Stasilojc, Grzegorz, Okroj, Marcin, Romanska, Hanna M., and Sadej, Rafal
- Abstract
Background: Genetic abnormalities in the FGFR signalling occur in 40% of breast cancer (BCa) patients resistant to anti-ER therapy, which emphasizes the potential of FGFR-targeting strategies. Recent findings indicate that not only mutated FGFR is a driver of tumour progression but co-mutational landscapes and other markers should be also investigated. Autophagy has been recognized as one of the major mechanisms underlying the role of tumour microenvironment in promotion of cancer cell survival, and resistance to anti-ER drugs. The selective autophagy receptor p62/SQSTM1 promotes Nrf-2 activation by Keap1/Nrf-2 complex dissociation. Herein, we have analysed whether the negative effect of FGFR2 on BCa cell response to anti-ER treatment involves the autophagy process and/or p62/Keap1/Nrf-2 axis. Methods: The activity of autophagy in ER-positive MCF7 and T47D BCa cell lines was determined by analysis of expression level of autophagy markers (p62 and LC3B) and monitoring of autophagosomes' maturation. Western blot, qPCR and proximity ligation assay were used to determine the Keap1/Nrf-2 interaction and Nrf-2 activation. Analysis of 3D cell growth in Matrigel® was used to assess BCa cell response to applied treatments. In silico gene expression analysis was performed to determine FGFR2/Nrf-2 prognostic value. Results: We have found that FGFR2 signalling induced autophagy in AMPKα/ULK1-dependent manner. FGFR2 activity promoted dissociation of Keap1/Nrf-2 complex and activation of Nrf-2. Both, FGFR2-dependent autophagy and activation of Nrf-2 were found to counteract the effect of anti-ER drugs on BCa cell growth. Moreover, in silico analysis showed that high expression of NFE2L2 (gene encoding Nrf-2) combined with high FGFR2 expression was associated with poor relapse-free survival (RFS) of ER+ BCa patients. Conclusions: This study revealed the unknown role of FGFR2 signalling in activation of autophagy and regulation of the p62/Keap1/Nrf-2 interdependence, which has a negative impact on the response of ER+ BCa cells to anti-ER therapies. The data from in silico analyses suggest that expression of Nrf-2 could act as a marker indicating potential benefits of implementation of anti-FGFR therapy in patients with ER+ BCa, in particular, when used in combination with anti-ER drugs. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
8. An estrogen-regulated long non-coding RNA NCALD promotes luminal breast cancer proliferation by activating GRHL2
- Author
-
Yue Meng, Dianrong Zhou, Ying Luo, Jierong Chen, and Hui Li
- Subjects
Luminal breast cancer ,LncRNA NCALD ,LncRNA ,GRHL2 ,ERα ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Cytology ,QH573-671 - Abstract
Abstract Purpose Luminal breast cancer (BC) is a prevalent subtype associated with an increased risk of late disease recurrence and mortality. Long noncoding RNAs (lncRNAs) likely play significant roles in regulating tissue-specific gene expression during tumorigenesis. However, the biological function and underlying mechanisms of specific dysregulated lncRNAs in luminal BC remain largely unknown, which has drawn our attention. Methods The expression pattern of lncRNA NCALD in luminal BC was predicted and validated in collected tissue samples. Following cell transfection with knockdown of lncRNA NCALD and ESR1 and overexpression of GRHL2 and ESR1, we investigated the interactions among lncRNA NCALD, ESR1, and GRHL2. Additionally, their regulatory functions in luminal BC cell biological processes were studied. Subsequently, a xenograft tumor model was prepared for validation. Results Our study identified a specific overexpression of the lncRNA NCALD in luminal BC, which correlated with an unfavorable prognosis. Suppression of lncRNA NCALD or ESR1 led to inhibition of GRHL2 expression, while concurrent overexpression of ESR1 and lncRNA NCALD potentially elevated GRHL2 expression. Mechanistically, ERα may drive the expression of lncRNA NCALD. Furthermore, the 1–151 nt fragment of lncRNA NCALD was found to recruit ERα and interact with its oest-Recep domain located in the promoter region of GRHL2, ultimately inducing GRHL2 transcription. Conclusions These findings reveal the involvement of lncRNA NCALD and its specific expression pattern in luminal BC. Targeting lncRNA NCALD could be a potential therapeutic strategy for delaying the progression of BC.
- Published
- 2024
- Full Text
- View/download PDF
9. Distinct profiles of proliferating CD8+/TCF1+ T cells and CD163+/PD-L1+ macrophages predict risk of relapse differently among treatment-naïve breast cancer subtypes.
- Author
-
Ntostoglou, Konstantinos, Theodorou, Sofia D. P., Proctor, Tanja, Nikas, Ilias P., Awounvo, Sinclair, Sepsa, Athanasia, Georgoulias, Vassilis, Ryu, Han Suk, Pateras, Ioannis S., and Kittas, Christos
- Subjects
- *
T cells , *BREAST cancer , *CANCER relapse , *PATIENT experience , *MACROPHAGES , *TRIPLE-negative breast cancer - Abstract
Immunophenotypic analysis of breast cancer microenvironment is gaining attraction as a clinical tool improving breast cancer patient stratification. The aim of this study is to evaluate proliferating CD8 + including CD8 + TCF1 + Τ cells along with PD-L1 expressing tissue-associated macrophages among different breast cancer subtypes. A well-characterized cohort of 791 treatment-naïve breast cancer patients was included. The analysis demonstrated a distinct expression pattern among breast cancer subtypes characterized by increased CD8 + , CD163 + and CD163 + PD-L1 + cells along with high PD-L1 status and decreased fraction of CD8 + Ki67 + T cells in triple negative (TNBC) and HER2 + compared to luminal tumors. Kaplan–Meier and Cox univariate survival analysis revealed that breast cancer patients with high CD8 + , CD8 + Ki67 + , CD8 + TCF1 + cells, PD-L1 score and CD163 + PD-L1 + cells are likely to have a prolonged relapse free survival, while patients with high CD163 + cells have a worse prognosis. A differential impact of high CD8 + , CD8 + Ki67 + , CD8 + TCF1 + T cells, CD163 + PD-L1 + macrophages and PD-L1 status on prognosis was identified among the various breast cancer subtypes since only TNBC patients experience an improved prognosis compared to patients with luminal A tumors. Conversely, high infiltration by CD163 + cells is associated with worse prognosis only in patients with luminal A but not in TNBC tumors. Multivariate Cox regression analysis in TNBC patients revealed that increased CD8 + [hazard ratio (HR) = 0.542; 95% confidence interval (CI) 0.309–0.950; p = 0.032), CD8 + TCF1 + (HR = 0.280; 95% CI 0.101–0.779; p = 0.015), CD163 + PD-L1 + (HR: 0.312; 95% CI 0.112–0.870; p = 0.026) cells along with PD-L1 status employing two different scoring methods (HR: 0.362; 95% CI 0.162–0.812; p = 0.014 and HR: 0.395; 95% CI 0.176–0.884; p = 0.024) were independently linked with a lower relapse rate. Multivariate analysis in Luminal type A patients revealed that increased CD163 + was independently associated with a higher relapse rate (HR = 2.360; 95% CI 1.077–5.170; p = 0.032). This study demonstrates that the evaluation of the functional status of CD8 + T cells in combination with the analysis of immunosuppressive elements could provide clinically relevant information in different breast cancer subtypes. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
10. Risk Factors of Response to Neoadjuvant Chemotherapy in Patients with Luminal (HER2 Negative) Breast Cancer: Roc Curve and Logistic Regression Model Results.
- Author
-
Bozdogan, Atilla, Emiroglu, Selman, Abuaisha, Asmaa, and Başar, Özlem Deniz
- Subjects
NEOADJUVANT chemotherapy ,BREAST cancer patients ,HER2 protein ,TRIPLE-negative breast cancer ,PROTEIN expression - Abstract
Background: Neoadjuvant chemotherapy (NAC) is less effective for luminal human epidermal growth factor receptor 2 (HER2) negative breast cancer (BC) patients and generally shows a low pathological complete response (pCR) after NAC compared to HER2 positive and triple negative breast cancer (TNBC). This study aimed to determine the factors associated with histopathologic response following NAC in luminal (HER2 negative) BC. Methods: This is a cross-sectional study conducted on 255 estrogen (ER) positive and HER2 negative BC patients after NAC between January 2018 and July 2023. Demographic and clinicopathological characteristics of the patients were collected for the statistical analysis. Chi-Square tests were used in the qualitative comparisons between study groups. Receiver Operating Characteristic (ROC) analysis was used for the diagnostic performance of Ki-67 expression and ER in determining the pCR rates. Using the Youden index, optimum cut points were determined. Also, multivariate logistic regression analysis was applied to determine the independent variables associated with the dependent variable (pCR). Results: After NAC, pCR was achieved in the breast in 35 (14%) patients, in the axilla in 44 (17%) patients, and in both the breast and axilla in 18 (7%) patients. Ki-67 expression was the only common variable associated with the breast, axilla and both the breast and axilla pCR. The most appropriate Ki-67 expression cut-off value for determining the breast and axilla complete response was found to be 40%. ER positivity level was only associated with pCR in the breast and the cut-off value was found to be 85%. Conclusion: The results of this study raise the possibility of patients with luminal (HER2 negative) BC with Ki-67 expression higher than 40% benefiting from chemotherapy, as they showed increased pCR rates. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
11. PIK3CA mutation presence as luminal breast cancer chemoresistance prognostic marker.
- Author
-
Volodimirovich, Movchan Oleksii, Ivanovich, Smolanka Ivan, Oleksandrovich, Lyashenko Andriy, Viktorivna, Dosenko Irina, Dmitrovich, Loboda Anton, and Mykolaivna, Ivankova Oksana
- Subjects
PROGNOSIS ,PATHOLOGIC complete response ,BREAST cancer ,DRUG resistance in cancer cells ,GENETIC mutation - Abstract
Breast Cancer (BC) is the major cause of morbidity and mortality among women in Ukraine and throughout the world, is characterized by a diverse set of gene alterations, the interaction between the tumor's molecular and genetic properties and the prognostic and clinical aspects. The National Comprehensive Cancer Network's (NCCN) Clinical Practice Guidelines for Breast Cancer indicate anthracycline with cyclophosphamide and taxane as a recommended Neoadjuvant Chemotherapy (NAC) strategy. Despite advances in disease prognosis and the overall advantages of chemotherapy, BC treatment frequently generates miscellaneous results in various groups. Drug resistance is a significant cause of cancer therapeutic failure. There is critical to investigate additional gene polymorphisms that may affect BC therapy responses. PIK3CA mutations are seen in around 25%-45% of BC, and they are more common in Hormone Receptor-Positive (HR+) patients. Although data have been extensively reported in BC, no study has focused on the molecular characterization and clinical outcome of patients with PIK3CAmutated Chemo-resistant (ChR) BC. According to researches, the oncogenic PIK3CA mutation pathway, in conjunction with other pathways, induces tumor aggressiveness and chemo-resistance. Therefore a need to better understand the characteristics of the ChRBC population harboring PIK3CA mutations. Resistance to neoadjuvant chemotherapy is related with PIK3CA mutations. This biomarker will be studied further for therapeutic utility in the treatment of luminal ChRBC patients. PIK3CA mutation was found to be unfavorable in patients with both overall and luminal BC, demonstrating the potential of PIK3CA mutation in combination with other multiple gene alterations and their relationships among themselves as detailed prognostic indicators in BC resistance subgroups. When the response to NAC and prognosis of breast cancerintrinsic subtypes were evaluated, patients with luminal tumors had a lower pathologic complete response rate, but better outcomes than triple negative and HER2 types. Similarly, luminal tumors with PIK3CA mutations exhibited chemo-resistance when compared to PIK3CA wild-type. [ABSTRACT FROM AUTHOR]
- Published
- 2024
12. An estrogen-regulated long non-coding RNA NCALD promotes luminal breast cancer proliferation by activating GRHL2.
- Author
-
Meng, Yue, Zhou, Dianrong, Luo, Ying, Chen, Jierong, and Li, Hui
- Subjects
- *
LINCRNA , *GENE expression , *BREAST cancer , *PROMOTERS (Genetics) , *DISEASE relapse , *CANCER relapse - Abstract
Purpose: Luminal breast cancer (BC) is a prevalent subtype associated with an increased risk of late disease recurrence and mortality. Long noncoding RNAs (lncRNAs) likely play significant roles in regulating tissue-specific gene expression during tumorigenesis. However, the biological function and underlying mechanisms of specific dysregulated lncRNAs in luminal BC remain largely unknown, which has drawn our attention. Methods: The expression pattern of lncRNA NCALD in luminal BC was predicted and validated in collected tissue samples. Following cell transfection with knockdown of lncRNA NCALD and ESR1 and overexpression of GRHL2 and ESR1, we investigated the interactions among lncRNA NCALD, ESR1, and GRHL2. Additionally, their regulatory functions in luminal BC cell biological processes were studied. Subsequently, a xenograft tumor model was prepared for validation. Results: Our study identified a specific overexpression of the lncRNA NCALD in luminal BC, which correlated with an unfavorable prognosis. Suppression of lncRNA NCALD or ESR1 led to inhibition of GRHL2 expression, while concurrent overexpression of ESR1 and lncRNA NCALD potentially elevated GRHL2 expression. Mechanistically, ERα may drive the expression of lncRNA NCALD. Furthermore, the 1–151 nt fragment of lncRNA NCALD was found to recruit ERα and interact with its oest-Recep domain located in the promoter region of GRHL2, ultimately inducing GRHL2 transcription. Conclusions: These findings reveal the involvement of lncRNA NCALD and its specific expression pattern in luminal BC. Targeting lncRNA NCALD could be a potential therapeutic strategy for delaying the progression of BC. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
13. AI‐based intra‐tumor heterogeneity score of Ki67 expression as a prognostic marker for early‐stage ER+/HER2− breast cancer.
- Author
-
Lu, Wenqi, Lashen, Ayat G, Wahab, Noorul, Miligy, Islam M, Jahanifar, Mostafa, Toss, Michael, Graham, Simon, Bilal, Mohsin, Bhalerao, Abhir, Atallah, Nehal M, Makhlouf, Shorouk, Ibrahim, Asmaa Y, Snead, David, Minhas, Fayyaz, Raza, Shan E Ahmed, Rakha, Emad, and Rajpoot, Nasir
- Subjects
BREAST ,EPIDERMAL growth factor receptors ,BREAST cancer ,PROGNOSIS ,ARTIFICIAL intelligence ,HETEROGENEITY ,ESTROGEN receptors - Abstract
Early‐stage estrogen receptor positive and human epidermal growth factor receptor negative (ER+/HER2−) luminal breast cancer (BC) is quite heterogeneous and accounts for about 70% of all BCs. Ki67 is a proliferation marker that has a significant prognostic value in luminal BC despite the challenges in its assessment. There is increasing evidence that spatial colocalization, which measures the evenness of different types of cells, is clinically important in several types of cancer. However, reproducible quantification of intra‐tumor spatial heterogeneity remains largely unexplored. We propose an automated pipeline for prognostication of luminal BC based on the analysis of spatial distribution of Ki67 expression in tumor cells using a large well‐characterized cohort (n = 2,081). The proposed Ki67 colocalization (Ki67CL) score can stratify ER+/HER2− BC patients with high significance in terms of BC‐specific survival (p < 0.00001) and distant metastasis‐free survival (p = 0.0048). Ki67CL score is shown to be highly significant compared with the standard Ki67 index. In addition, we show that the proposed Ki67CL score can help identify luminal BC patients who can potentially benefit from adjuvant chemotherapy. [ABSTRACT FROM AUTHOR]
- Published
- 2024
- Full Text
- View/download PDF
14. Rationale for the Initiation, Outcomes, and Characteristics of Chemotherapy Following CDK4/6 Inhibitors in Breast Cancer: A Real-World Cohort Study
- Author
-
Miroslawa Püsküllüoğlu, Marek Ziobro, Joanna Lompart, Agnieszka Rudzińska, Tomasz Zemełka, Justyna Jaworska, Sebastian Ochenduszko, and Aleksandra Grela-Wojewoda
- Subjects
luminal breast cancer ,metastases ,chemotherapy ,CDK4/6 inhibitors ,systemic treatment ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
The standard therapy for hormone-receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer includes the use of cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) with endocrine therapy. The optimal post-CDK4/6i treatment sequence is unclear. This cohort study evaluated the initiation, characteristics, and outcomes of chemotherapy following CDK4/6i-based treatment. Among the 227 patients who began CDK4/6i therapy, 114 completed it. Seventy-nine female patients received further treatment, including 55 receiving chemotherapy. The average age was 60.1 years. Post-CDK4/6i chemotherapy was typically (69.1%) first-line due to an impending visceral crisis. The median progression-free survival (mPFS) was 3.0 months (range 0.5–18.9), and the median overall survival (mOS) was 8.3 months (0.5–26.1). The median OS from the end of CDK4/6i treatment was 12.4 months (1.5–26.8). In univariate analysis, neither mPFS nor mOS was associated with age, tumor grade, receptor status, Ki67 status, time from diagnosis to CDK4/6i cessation, therapy line, or CDK4/6i type. Dose reduction occurred in 12 patients (21.8%), and chemotherapy was ceased due to adverse events in 8 patients (14.6%). Chemotherapy showed limited benefit regardless of the regimen. The role of chemotherapy may evolve with broader CDK4/6i use in adjuvant treatment.
- Published
- 2024
- Full Text
- View/download PDF
15. Association of SLC12A1 and GLUR4 Ion Transporters with Neoadjuvant Chemoresistance in Luminal Locally Advanced Breast Cancer.
- Author
-
Justo-Garrido, Montserrat, López-Saavedra, Alejandro, Alcaraz, Nicolás, Cortés-González, Carlo C., Oñate-Ocaña, Luis F., Caro-Sánchez, Claudia Haydee Sarai, Castro-Hernández, Clementina, Arriaga-Canon, Cristian, Díaz-Chávez, José, and Herrera, Luis A.
- Subjects
- *
METASTATIC breast cancer , *DRUG resistance in cancer cells , *ION transport (Biology) , *GENE expression , *BREAST , *HORMONE receptors , *NEOADJUVANT chemotherapy , *EXCITATORY amino acids - Abstract
Chemoresistance to standard neoadjuvant treatment commonly occurs in locally advanced breast cancer, particularly in the luminal subtype, which is hormone receptor-positive and represents the most common subtype of breast cancer associated with the worst outcomes. Identifying the genes associated with chemoresistance is crucial for understanding the underlying mechanisms and discovering effective treatments. In this study, we aimed to identify genes linked to neoadjuvant chemotherapy resistance in 62 retrospectively included patients with luminal breast cancer. Whole RNA sequencing of 12 patient biopsies revealed 269 differentially expressed genes in chemoresistant patients. We further validated eight highly correlated genes associated with resistance. Among these, solute carrier family 12 member 1 (SLC12A1) and glutamate ionotropic AMPA type subunit 4 (GRIA4), both implicated in ion transport, showed the strongest association with chemoresistance. Notably, SLC12A1 expression was downregulated, while protein levels of glutamate receptor 4 (GLUR4), encoded by GRIA4, were elevated in patients with a worse prognosis. Our results suggest a potential link between SLC12A1 gene expression and GLUR4 protein levels with chemoresistance in luminal breast cancer. In particular, GLUR4 protein could serve as a potential target for drug intervention to overcome chemoresistance. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
16. Oncogenic PIK3CA recruits myeloid‐derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5‐lipoxygenase‐dependent arachidonic acid pathway.
- Author
-
Li, Xingchen, Chen, Guidong, Wang, Fanchen, Guo, Xiaojing, Zhang, Rui, Liu, Pengpeng, Dong, Li, Yu, Wenwen, Wang, Huan, Wang, Hailong, and Yu, Jinpu
- Subjects
- *
MYELOID-derived suppressor cells , *CELL morphology , *ARACHIDONIC acid , *CYTOTOXIC T cells , *TUMOR microenvironment - Abstract
Background: Oncogenic PIK3CA mutations (PIK3CAmut) frequently occur in a higher proportion in luminal breast cancer (LBC), especially in refractory advanced cases, and are associated with changes in tumour cellular metabolism. Nevertheless, its effect on the progression of the immune microenvironment (TIME) within tumours and vital molecular events remains veiled. Methods: Multiplex immunohistochemistry (mIHC) and single‐cell mass cytometry (CyTOF) was used to describe the landscape of TIME in PIK3CAmut LBC. The PIK3CA mutant cell lines were established using CRISPER/Cas9 system. The gene expression levels, protein secretion and activity of signaling pathways were measured by real‐time RT‐PCR, ELISA, immunofluorescence staining or western blotting. GSEA analysis, transwell chemotaxis assay, live cell imaging, flow cytometry metabolite analysis targeting arachidonic acid, Dual‐luciferase reporter assay, and Chromatin immunoprecipitation assay were used to investigate the underlying function and mechanism of the PI3K/5‐LOX/LTB4 axis. Results: PIK3CAmut LBC cells can induce an immunosuppressive TIME by recruiting myeloid‐derived suppressor cells (MDSCs) and excluding cytotoxic T cells via the arachidonic acid (AA) metabolism pathway. Mechanistically, PIK3CAmut activates the transcription of 5‐lipoxygenase (5‐LOX) in a STAT3‐dependent manner, which in turn directly results in high LTB4 production, binding to BLT2 on MDSCs and promoting their infiltration. Since a suppressive TIME is a critical barrier for the success of cancer immunotherapy, the strategies that can convert "cold" tumours into "hot" tumours were compared. Targeted therapy against the PI3K/5‐LOX/LTB4 axis synergizing with immune checkpoint blockade (ICB) therapy achieved dramatic shrinkage in vivo. Conclusions: The results emphasize that PIK3CAmut can induce immune evasion by recruiting MDSCs through the 5‐LOX‐dependent AA pathway, and combination targeted therapy with ICB may provide a promising treatment option for refractory advanced LBC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
17. AI‐based intra‐tumor heterogeneity score of Ki67 expression as a prognostic marker for early‐stage ER+/HER2− breast cancer
- Author
-
Wenqi Lu, Ayat G Lashen, Noorul Wahab, Islam M Miligy, Mostafa Jahanifar, Michael Toss, Simon Graham, Mohsin Bilal, Abhir Bhalerao, Nehal M Atallah, Shorouk Makhlouf, Asmaa Y Ibrahim, David Snead, Fayyaz Minhas, Shan E Ahmed Raza, Emad Rakha, and Nasir Rajpoot
- Subjects
AI based prognostic biomarkers ,computational pathology ,Ki67 expression ,luminal breast cancer ,Pathology ,RB1-214 - Abstract
Abstract Early‐stage estrogen receptor positive and human epidermal growth factor receptor negative (ER+/HER2−) luminal breast cancer (BC) is quite heterogeneous and accounts for about 70% of all BCs. Ki67 is a proliferation marker that has a significant prognostic value in luminal BC despite the challenges in its assessment. There is increasing evidence that spatial colocalization, which measures the evenness of different types of cells, is clinically important in several types of cancer. However, reproducible quantification of intra‐tumor spatial heterogeneity remains largely unexplored. We propose an automated pipeline for prognostication of luminal BC based on the analysis of spatial distribution of Ki67 expression in tumor cells using a large well‐characterized cohort (n = 2,081). The proposed Ki67 colocalization (Ki67CL) score can stratify ER+/HER2− BC patients with high significance in terms of BC‐specific survival (p
- Published
- 2024
- Full Text
- View/download PDF
18. GLUL gene knockdown and restricted glucose level show synergistic inhibitory effect on the luminal subtype breast cancer MCF7 cells’ proliferation and metastasis
- Author
-
Arezu Karimpur Zahmatkesh, Mohammad Khalaj-Kondori, Mohammad Ali Hosseinpour Feizi, and Behzad Baradaran
- Subjects
cancer metabolism ,glutamine synthetase ,glycolysis ,luminal breast cancer ,mcf7 cell line ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 ,Biology (General) ,QH301-705.5 - Abstract
The glutamine synthetase path is one of the most important metabolic pathways in luminal breast cancer cells, which plays a critical role in supplying glutamine as an intermediate in the biosynthesis of amino acids and nucleotides. On the other hand, glycolysis and its dominant substrate, glucose, are the most critical players in cancer metabolism. Accordingly, targeting these two critical paths might be more efficient in luminal-type breast cancer treatment. MCF7 cells were cultivated in media containing 4.5, 2, and 1 g/L glucose to study its effects on GLUL (Glutamate Ammonia Ligase) expression. Followingly, high and low glucose cell cultures were transfected with 220 pM of siGLUL and incubated for 48 h at 37 ºC. The cell cycle progression and apoptosis were monitored and assessed by flow cytometry. Expression of GLUL, known as glutamine synthetase, was evaluated in mRNA and protein levels by qRT-PCR and western blotting, respectively. To examine the migration and invasion capacity of studied cells exploited from wound healing assay and subsequent expression studies of glutathione-S-transferase Mu3 (GSTM3) and alfa-enolase (ENO1). Expression of GLUL significantly decreased in cells cultured at lower glucose levels compared to those at higher glucose levels. siRNA-mediated knockdown of GLUL expression in low glucose cultures significantly reduced growth, proliferation, migration, and invasion of the MCF7 cells and enhanced their apoptosis compared to the controls. Based on the results, GLUL suppression down-regulated GSTM3, a main detoxifying enzyme, and up-regulated Bax. According to the role of glycolysis as a ROS suppressor, decreased amounts of glucose could be associated with increased ROS; it can be considered an efficient involved mechanism in this study. Also, increased expression of Bax could be attributable to mTOR/AKT inhibition following GLUL repression. In conclusion, utilizing GLUL and glycolysis inhibitors might be a more effective strategy in luminal-type breast cancer therapy.
- Published
- 2023
- Full Text
- View/download PDF
19. Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients
- Author
-
Muhan Yu, Mamoru Takada, Hideyuki Yamada, Hiroshi Fujimoto, Junta Sakakibara, Hiroto Yamamoto, Takeshi Nagashima, and Masayuki Ohtsuka
- Subjects
adjuvant therapy ,CDK4/6 ,early breast cancer ,inhibitor ,luminal breast cancer ,monarchE ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Abstract Background In monarchE and Postoperative Therapy with Endocrine and TS‐1 (POTENT) trials, abemaciclib and S‐1 have, respectively, shown to be effective as adjuvant therapies for luminal breast cancer (BC), although whether patients who meet the criteria are at high risk of recurrence compared to non‐eligible patients is still unknown. Here, we investigated recurrence risk according to the criteria of each trial in Japanese patients. Methods We reviewed the records of 992 patients who received surgery at Chiba University Hospital for stage I–III BC from January 2017 to May 2022 and selected 553 analytic cohort patients and retrospectively analyzed the relapse‐free survival of the patients as the primary endpoint. High‐recurrence risk was defined according to monarchE trial and POTENT trial. Results The 5‐year RFS for monarchE cohort 1 and cohort 2 eligible patients were 77.78% and 89.33%, respectively, which were significantly lower than monarchE non‐eligible patients (98.31%; p
- Published
- 2023
- Full Text
- View/download PDF
20. Oncogenic PIK3CA recruits myeloid‐derived suppressor cells to shape the immunosuppressive tumour microenvironment in luminal breast cancer through the 5‐lipoxygenase‐dependent arachidonic acid pathway
- Author
-
Xingchen Li, Guidong Chen, Fanchen Wang, Xiaojing Guo, Rui Zhang, Pengpeng Liu, Li Dong, Wenwen Yu, Huan Wang, Hailong Wang, and Jinpu Yu
- Subjects
arachidonic acid ,luminal breast cancer ,myeloid‐derived suppressor cells ,PIK3CA ,tumour immune microenvironment ,Medicine (General) ,R5-920 - Abstract
Background: Oncogenic PIK3CA mutations (PIK3CAmut) frequently occur in a higher proportion in luminal breast cancer (LBC), especially in refractory advanced cases, and are associated with changes in tumour cellular metabolism. Nevertheless, its effect on the progression of the immune microenvironment (TIME) within tumours and vital molecular events remains veiled. Methods: Multiplex immunohistochemistry (mIHC) and single‐cell mass cytometry (CyTOF) was used to describe the landscape of TIME in PIK3CAmut LBC. The PIK3CA mutant cell lines were established using CRISPER/Cas9 system. The gene expression levels, protein secretion and activity of signaling pathways were measured by real‐time RT‐PCR, ELISA, immunofluorescence staining or western blotting. GSEA analysis, transwell chemotaxis assay, live cell imaging, flow cytometry metabolite analysis targeting arachidonic acid, Dual‐luciferase reporter assay, and Chromatin immunoprecipitation assay were used to investigate the underlying function and mechanism of the PI3K/5‐LOX/LTB4 axis. Results: PIK3CAmut LBC cells can induce an immunosuppressive TIME by recruiting myeloid‐derived suppressor cells (MDSCs) and excluding cytotoxic T cells via the arachidonic acid (AA) metabolism pathway. Mechanistically, PIK3CAmut activates the transcription of 5‐lipoxygenase (5‐LOX) in a STAT3‐dependent manner, which in turn directly results in high LTB4 production, binding to BLT2 on MDSCs and promoting their infiltration. Since a suppressive TIME is a critical barrier for the success of cancer immunotherapy, the strategies that can convert “cold” tumours into “hot” tumours were compared. Targeted therapy against the PI3K/5‐LOX/LTB4 axis synergizing with immune checkpoint blockade (ICB) therapy achieved dramatic shrinkage in vivo. Conclusions: The results emphasize that PIK3CAmut can induce immune evasion by recruiting MDSCs through the 5‐LOX‐dependent AA pathway, and combination targeted therapy with ICB may provide a promising treatment option for refractory advanced LBC patients.
- Published
- 2023
- Full Text
- View/download PDF
21. Neoadjuvant endocrine therapy in ER-positive breast cancer: evolution, indication, and tailored treatment strategy.
- Author
-
Jeong, Hyehyun and Kim, Sung-Bae
- Abstract
In recent years, endocrine therapy (ET), an effective systemic treatment for the management of estrogen receptor (ER)-positive breast cancers, has regained interest as a neoadjuvant therapy based on evidence that ET can fulfill the aim of neoadjuvant systemic treatment for tumor shrinkage as well as elucidate important clinical information on endocrine sensitivity that enables the prognostication of patients. Moreover, neoadjuvant endocrine therapy (NET) potentially provides an opportunity for early assessment of the clinical efficacy of novel agents. Furthermore, recently reported trials have generated evidence for a more tailored approach for perioperative management of ER-positive breast cancer using clinical and molecular biomarkers, and this has provided a rationale that enables the broadening of clinical indications for NET. This review discusses the current evidence for NET, the evolution of NET trials, clinical indications, and NET-based treatment strategies. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
22. Tumor Infiltrating Lymphocytes (TILS) and PD-L1 Expression in Breast Cancer: A Review of Current Evidence and Prognostic Implications from Pathologist's Perspective.
- Author
-
Angelico, Giuseppe, Broggi, Giuseppe, Tinnirello, Giordana, Puzzo, Lidia, Vecchio, Giada Maria, Salvatorelli, Lucia, Memeo, Lorenzo, Santoro, Angela, Farina, Jessica, Mulé, Antonino, Magro, Gaetano, and Caltabiano, Rosario
- Subjects
- *
BREAST cancer prognosis , *BREAST tumor treatment , *LYMPHOCYTE metabolism , *ADJUVANT chemotherapy , *PROGRAMMED death-ligand 1 , *PATHOLOGISTS , *CANCER chemotherapy , *IMMUNOHISTOCHEMISTRY , *EVIDENCE-based medicine , *GENE expression , *PSYCHOSOCIAL factors , *COMBINED modality therapy , *TUMOR markers , *BREAST tumors , *IMMUNOTHERAPY - Abstract
Simple Summary: The aim of our study is to provide a wide perspective on the available literature data on the immune landscape of breast cancers, focusing on TILs and PD-L1 expression across different breast cancer subtypes. Moreover, treatment options such as immunotherapy and chemotherapy in adjuvant and neoadjuvant settings are discussed, along with the most relevant cut-offs and scores for TILs and PD-L1 pathological assessment. With the rise of novel immunotherapies able to stimulate the antitumor immune response, increasing literature concerning the immunogenicity of breast cancer has been published in recent years. Numerous clinical studies have been conducted in order to identify novel biomarkers that could reflect the immunogenicity of BC and predict response to immunotherapy. In this regard, TILs have emerged as an important immunological biomarker related to the antitumor immune response in BC. TILs are more frequently observed in triple-negative breast cancer and HER2+ subtypes, where increased TIL levels have been linked to a better response to neoadjuvant chemotherapy and improved survival. PD-L1 is a type 1 transmembrane protein ligand expressed on T lymphocytes, B lymphocytes, and antigen-presenting cells and is considered a key inhibitory checkpoint involved in cancer immune regulation. PD-L1 immunohistochemical expression in breast cancer is observed in about 10–30% of cases and is extremely variable based on tumor stage and molecular subtypes. Briefly, TNBC shows the highest percentage of PD-L1 positivity, followed by HER2+ tumors. On the other hand, PD-L1 is rarely expressed (0–10% of cases) in hormone-receptor-positive BC. The prognostic role of PD-L1 expression in BC is still controversial since different immunohistochemistry (IHC) clones, cut-off points, and scoring systems have been utilized across published studies. In the present paper, an extensive review of the current knowledge of the immune landscape of BC is provided. TILS and PD-L1 expression across different BC subtypes are discussed, providing a guide for their pathological assessment and reporting. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
23. Erxian Decoction Enhances the Tamoxifen Sensitivity in Luminal Breast Cancer through the PI3K‐AKT Signaling Pathway.
- Author
-
Wang, Xinbin, Zhang, Zhongwen, Wang, Haorui, Ma, Ruiling, Zhang, Yi, and Wang, Rong
- Subjects
- *
CELLULAR signal transduction , *MOLECULES , *BREAST cancer , *TAMOXIFEN , *LUTEOLIN - Abstract
Background: The primary and secondary resistance of luminal breast cancer (LBC) against endocrine therapy is a serious clinical problem. At present, it has been confirmed that Erxian Decoction can improve the sensitivity of LBC to tamoxifen (TAM), but its mechanism is not clear. The purpose of this paper is to explore the molecular mechanism that causes Erxian Decoction to increase the sensitivity of LBC to TAM. Methods: The potential targets and related pathways of Erxian Decoction inhibiting LBC were screened through bioinformatics. The small molecular compounds that could stably bind to LBC targets were determined by molecular docking. The stable interaction of the target and the small molecular compounds was revealed by the cell thermal shift assay (CETSA). Cell Counting Kit‐8 (CCK‐8) was used to verify the effect of Erxian Decoction and TAM on the cell activity of LBC. Flow cytometry was used to verify the effect of Erxian Decoction and TAM on the apoptosis of LBC cells. Western blot was used to detect the expression of PI3K‐AKT pathway‐related proteins in cells. Results: ERBB2 was screened as a potential target for the treatment of LBC. Based on molecular docking and CETSA results, the stable interaction between luteolin and ERBB2 was confirmed. CCK‐8 results showed that luteolin could inhibit the cell activity of LBC, and luteolin treatment could improve the drug sensitivity of tumor cells to TAM. The results of flow cytometry showed that compared with TAM treatment alone, the addition of luteolin trefatment promoted the apoptosis level of LBC cells. Western blot results indicated that luteolin could inhibit the PI3K‐AKT signal pathway by combining with ERBB2. Conclusion: Luteolin in Erxian Decoction inhibited the progression of LBC and enhanced the sensitivity of LBC to TAM by binding with ERBB2 to down‐regulate the activity of the PI3K‐AKT signaling pathway. This study provided theoretical support for endocrine therapy of TAM‐resistant LBC patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
24. Platelet Concentration and Platelet/Lymphocyte Ratio as Prognostic Indicators in Luminal Breast Cancer
- Author
-
Angela Della’Santa Rubio O. Rönnau, Maiquidieli Dal Berto, Claudia Giuliano Bica, Rafael Vargas Alves, and Liane Nanci Rotta
- Subjects
luminal breast cancer ,prognosis ,platelet ,platelet/lymphocyte ratio ,Pathology ,RB1-214 - Abstract
Ratios between the blood cells are indirect measures of the imbalance in the pro-inflammatory status observed in carcinogenesis and have been proposed as accessible and feasible biomarkers to predict cancer prognosis. We aim to evaluate the prognostic significance of neutrophil/lymphocyte (NLR), monocyte/lymphocyte (MLR), and platelet/lymphocyte (PLR) ratios in Brazilian patients with luminal breast cancer (LBC) treated with tamoxifen. A retrospective cohort of 72 operable LBC patients. Preoperative leukocyte and platelet absolute values permitted to calculate NLR, MLR, and PLR. Area under curve (ROC) determined the cutoff value associated with relapse and death. Univariate and multivariate analyses were used to assess the relationship of the platelet and PLR to disease-free survival (DFS) and overall survival (OS). Lower DFS was associated with >297 × 103/mm3 (54 vs. 60.9 months in p = 0.04). Platelet > 279 × 103/mm3 are related to higher OS (p = 0.03). Univariate analysis revealed that platelet concentration was associated with DFS (p = 0.04) and OS (p = 0.04), but not as an independent factor (HR = 1.31, 95%CI: 0.42–4.07, p = 0.65) and OS (HR = 1.64, 95%CI: 0.28–9.52, p = 0.58). Both univariate (p = 0.01) and multivariate analysis revealed that PLR < 191.5 was a significant independent predictor of higher OS/better prognosis (HR = 16.16, 95%CI: 2.83–109.25, p = 0.00). Pretreatment platelet indices (absolute count and PLR) are prognosis predictors in LBC patients. Platelet > 279 × 103/mm3 and PRL < 191.5 was associated with a higher OS, with the PRL being an independent predictor of higher OS.
- Published
- 2023
- Full Text
- View/download PDF
25. Ribociclib in newly diagnosed hepatitis B infection: A case report.
- Author
-
Di Costanzo, Fabrizio, Carrano, Simone, Iengo, Gennaro, Cefaliello, Amedeo, Cossiga, Valentina, Morisco, Filomena, Giuliano, Mario, De Angelis, Carmine, and Arpino, Grazia
- Subjects
HEPATITIS B ,EPIDERMAL growth factor receptors ,METASTATIC breast cancer ,CYCLIN-dependent kinase inhibitors ,CARDIOVASCULAR diseases ,INFECTION - Abstract
Breast cancer is the most frequently diagnosed cancer in women worldwide. Actually CDK4/6 inhibitor Ribociclib is approved for the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)- negative breast cancer, but comorbidities like infectious or cardiovascular diseases may limit its use. Case report: A 45-year-old woman was diagnosed with metastatic breast cancer in September 2021; also, her hepatitis screening resulted positive for hepatitis B infection. Patient assumed eradicative therapy for hepatitis and bit after started oncological therapy with Ribociclib. Outcome: Frequent check of hepatological function was observed since start of eradicative therapy; liver transaminases and bilirubin kept to not rise despite start of oncological treatment with Ribociclib. Patient's Performance Status was also not compromised and revaluation at 4, 9 and 13 months showed partial response and then stable disease. Discussion: hepatotoxicity of Ribociclib is reported as a possible side effect, and often positivity for hepatitis is cause of exclusion from therapy; in our case, no hepatotoxicity was noted and patient obtained response in terms of control of both infectious and oncological diseases. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
26. Top advances of the year: Breast cancer.
- Author
-
Saavedra, Cristina, Gion, María, Cortés, Javier, and Llombart‐Cussac, Antonio
- Subjects
- *
TRIPLE-negative breast cancer , *BREAST cancer , *ANTIBODY-drug conjugates , *HER2 positive breast cancer , *INDIVIDUALIZED medicine - Abstract
Although breast cancer has led the way toward precision medicine, more research is still needed to increase curation rates in patients with early disease and to prolong survival with an optimal quality of life in the metastatic setting. Last year, big advances were achieved toward these goals thanks to the significant impact of immunotherapy on survival in triple‐negative breast cancer and the exciting results of antibody‐drug conjugates. Plain Language Summary: The development of new drugs and biomarkers to select those patients who will benefit of them are crucial in improving survival in breast cancer.Last year, the emergence of antibody‐drug conjugates and the reaffirmation of the potential of immunotherapy in breast cancer were the most important findings. The definitive establishment of immunotherapy in triple‐negative breast cancer and the amazing results of the new antibody‐drug conjugates are the main landmarks in 2021 and 2022, and constitute the beginning of a new era in the treatment of breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
27. Less necessity of adjuvant S‐1 treatment in non‐monarchE‐eligible patients.
- Author
-
Yu, Muhan, Takada, Mamoru, Yamada, Hideyuki, Fujimoto, Hiroshi, Sakakibara, Junta, Yamamoto, Hiroto, Nagashima, Takeshi, and Ohtsuka, Masayuki
- Subjects
- *
JAPANESE people , *HORMONE therapy , *UNIVERSITY hospitals , *BREAST cancer - Abstract
Background: In monarchE and Postoperative Therapy with Endocrine and TS‐1 (POTENT) trials, abemaciclib and S‐1 have, respectively, shown to be effective as adjuvant therapies for luminal breast cancer (BC), although whether patients who meet the criteria are at high risk of recurrence compared to non‐eligible patients is still unknown. Here, we investigated recurrence risk according to the criteria of each trial in Japanese patients. Methods: We reviewed the records of 992 patients who received surgery at Chiba University Hospital for stage I–III BC from January 2017 to May 2022 and selected 553 analytic cohort patients and retrospectively analyzed the relapse‐free survival of the patients as the primary endpoint. High‐recurrence risk was defined according to monarchE trial and POTENT trial. Results: The 5‐year RFS for monarchE cohort 1 and cohort 2 eligible patients were 77.78% and 89.33%, respectively, which were significantly lower than monarchE non‐eligible patients (98.31%; p < 0.0001). However, the 5‐year RFS rate for POTENT eligible patients (90.51%) was lower than for POTENT non‐eligible patients (98.75%; p = 0.0001); excluding those who met the monarchE criteria, the prognosis of POTENT eligible patients had no significant differences from the prognosis of patients with POTENT non‐eligible BC (p = 0.3100). Conclusion: MonarchE criteria accurately identify patients who are prone to relapse. Moreover, although POTENT criteria also suggested a reasonable capacity for recurrence prediction, there was no significant difference in recurrence between POTENT non‐eligible patients and the patients who were POTENT but not monarchE eligible. This might offer justification for reconsidering the use of S‐1 in monarchE non‐eligible patients. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
28. CNVs in 8q24.3 do not influence gene co-expression in breast cancer subtypes.
- Author
-
Hernández-Gómez, Candelario, Hernández-Lemus, Enrique, and Espinal-Enríquez, Jesús
- Subjects
BRCA genes ,HER2 positive breast cancer ,GENE regulatory networks ,BREAST cancer ,GENETIC disorders ,GENE expression ,BREAST - Abstract
Gene co-expression networks are a useful tool in the study of interactions that have allowed the visualization and quantification of diverse phenomena, including the loss of co-expression over long distances in cancerous samples. This characteristic, which could be considered fundamental to cancer, has been widely reported in various types of tumors. Since copy number variations (CNVs) have previously been identified as causing multiple genetic diseases, and gene expression is linked to them, they have often been mentioned as a probable cause of loss of co-expression in cancerous networks. In order to carry out a comparative study of the validity of this statement, we took 477 proteincoding genes from chromosome 8, and the CNVs of 101 genes, also proteincoding, belonging to the 8q24.3 region, a cytoband that is particularly active in the appearance of breast cancer. We created CNVS-conditioned co-expression networks of each of the 101 genes in the 8q24.3 region using conditional mutual information. The study was carried out using the four molecular subtypes of breast cancer (Luminal A, Luminal B, Her2, and Basal), as well as a case corresponding to healthy samples. We observed that in all cancer cases, the measurement of the Kolmogorov-Smirnov statistic shows that there are no significant differences between one and other values of the CNVs for any case. Furthermore, the co-expression interactions are stronger in all cancer subtypes than in the control networks. However, the control network presents a homogeneously distributed set of co-expression interactions, while for cancer networks, the highest interactions are more confined to specific cytobands, in particular 8q24.3 and 8p21.3. With this approach, we demonstrate that despite copy number alterations in the 8q24 region being a common trait in breast cancer, the loss of long-distance co-expression in breast cancer is not determined by CNVs. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
29. FGF7/FGFR2–JunB signalling counteracts the effect of progesterone in luminal breast cancer
- Author
-
Kamil Mieczkowski, Kamila Kitowska, Marcin Braun, Barbara Galikowska‐Bogut, Monika Gorska‐Arcisz, Dominika Piasecka, Konrad Stawiski, Anna J. Zaczek, Dariusz Nejc, Radzisław Kordek, Hanna M. Romanska, and Rafal Sadej
- Subjects
ER ,FGFR2 ,JunB ,luminal breast cancer ,PR ,steroid hormones ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
We have recently demonstrated that fibroblast growth factor receptor 2 (FGFR2)‐mediated signalling alters progesterone receptor (PR) activity and response of oestrogen receptor α (ER)‐positive (ER+) breast cancer (BCa) cell lines to anti‐ER agents. Little is known about whether the crosstalk between ER and PR, shown to be modulated by the hormonal background, might also be affected by FGFR2. Here, PR‐dependent behaviour of ER+ BCa cells was studied in the presence of oestrogen (E2) and progesterone (P4) and/or FGF7. In vitro analyses showed that FGF7/FGFR2 signalling: (a) abolished the effect of P4 on E2‐promoted 3D cell growth and response to tamoxifen; (b) regulated ER and PR expression and activity; (c) increased formation of ER–PR complexes; and (d) reversed P4‐triggered deregulation of ER‐dependent genes. Analysis of clinical data demonstrated that the prognostic value of FGFR2 varied between patients with different menopausal status; that is, high expression of FGFR2 was significantly associated with longer progression‐free survival (PFS) in postmenopausal patients, whereas there was no significant association in premenopausal patients. FGFR2 was found to positively correlate with the expression of JunB proto‐oncogene, AP‐1 transcription factor subunit (JUNB), an ER‐dependent gene, only in premenopausal patients. Molecular analyses revealed that the presence of JunB was a prerequisite for FGFR2‐mediated abrogation of P4‐induced inhibition of cell growth. Our results demonstrate for the first time that the FGF7/FGFR2–JunB axis abolishes the modulatory effects of PR on ER‐associated biological functions in premenopausal ER+ BCa. This may provide foundations for a better selection of patients for FGFR‐targeting therapeutic strategies.
- Published
- 2022
- Full Text
- View/download PDF
30. Development of a nomogram for predicting pathological complete response in luminal breast cancer patients following neoadjuvant chemotherapy.
- Author
-
Garufi, Giovanna, Carbognin, Luisa, Sperduti, Isabella, Miglietta, Federica, Dieci, Maria Vittoria, Mazzeo, Roberta, Orlandi, Armando, Gerratana, Lorenzo, Palazzo, Antonella, Fabi, Alessandra, Paris, Ida, Franco, Antonio, Franceschini, Gianluca, Fiorio, Elena, Pilotto, Sara, Guarneri, Valentina, Puglisi, Fabio, Conte, Pierfranco, Milella, Michele, and Scambia, Giovanni
- Abstract
Background: Given the low chance of response to neoadjuvant chemotherapy (NACT) in luminal breast cancer (LBC), the identification of predictive factors of pathological complete response (pCR) represents a challenge. A multicenter retrospective analysis was performed to develop and validate a predictive nomogram for pCR, based on pre-treatment clinicopathological features. Methods: Clinicopathological data from stage I–III LBC patients undergone NACT and surgery were retrospectively collected. Descriptive statistics was adopted. A multivariate model was used to identify independent predictors of pCR. The obtained log-odds ratios (ORs) were adopted to derive weighting factors for the predictive nomogram. The receiver operating characteristic analysis was applied to determine the nomogram accuracy. The model was internally and externally validated. Results: In the training set, data from 539 patients were gathered: pCR rate was 11.3% [95% confidence interval (CI): 8.6–13.9] (luminal A-like: 5.3%, 95% CI: 1.5–9.1, and luminal B-like: 13.1%, 95% CI: 9.8–13.4). The optimal Ki67 cutoff to predict pCR was 44% (area under the curve (AUC): 0.69; p < 0.001). Clinical stage I–II (OR: 3.67, 95% CI: 1.75–7.71, p = 0.001), Ki67 ⩾44% (OR: 3.00, 95% CI: 1.59–5.65, p = 0.001), and progesterone receptor (PR) <1% (OR: 2.49, 95% CI: 1.15–5.38, p = 0.019) were independent predictors of pCR, with high replication rates at internal validation (100%, 98%, and 87%, respectively). According to the nomogram, the probability of pCR ranged from 3.4% for clinical stage III, PR > 1%, and Ki67 <44% to 53.3% for clinical stage I–II, PR < 1%, and Ki67 ⩾44% (accuracy: AUC, 0.73; p < 0.0001). In the validation set (248 patients), the predictive performance of the model was confirmed (AUC: 0.7; p < 0.0001). Conclusion: The combination of commonly available clinicopathological pre-NACT factors allows to develop a nomogram which appears to reliably predict pCR in LBC. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
31. Platelet Concentration and Platelet/Lymphocyte Ratio as Prognostic Indicators in Luminal Breast Cancer.
- Author
-
Rubio O. Rönnau, Angela Della'Santa, Dal Berto, Maiquidieli, Giuliano Bica, Claudia, Vargas Alves, Rafael, and Nanci Rotta, Liane
- Subjects
- *
PLATELET lymphocyte ratio , *BREAST cancer prognosis , *BLOOD cells , *BIOMARKERS , *PROGRESSION-free survival - Abstract
Ratios between the blood cells are indirect measures of the imbalance in the pro-inflammatory status observed in carcinogenesis and have been proposed as accessible and feasible biomarkers to predict cancer prognosis. We aim to evaluate the prognostic significance of neutrophil/lymphocyte (NLR), monocyte/lymphocyte (MLR), and platelet/lymphocyte (PLR) ratios in Brazilian patients with luminal breast cancer (LBC) treated with tamoxifen. A retrospective cohort of 72 operable LBC patients. Preoperative leukocyte and platelet absolute values permitted to calculate NLR, MLR, and PLR. Area under curve (ROC) determined the cutoff value associated with relapse and death. Univariate and multivariate analyses were used to assess the relationship of the platelet and PLR to disease-free survival (DFS) and overall survival (OS). Lower DFS was associated with >297 x 103/mm3 (54 vs. 60.9 months in <297, p = 0.04). Platelet > 279 x 103/mm3 are related to higher OS (p = 0.03). Univariate analysis revealed that platelet concentration was associated with DFS (p = 0.04) and OS (p = 0.04), but not as an independent factor (HR = 1.31, 95%CI: 0.42-4.07, p = 0.65) and OS (HR = 1.64, 95%CI: 0.28-9.52, p = 0.58). Both univariate (p = 0.01) and multivariate analysis revealed that PLR < 191.5 was a significant independent predictor of higher OS/better prognosis (HR = 16.16, 95%CI: 2.83-109.25, p = 0.00). Pretreatment platelet indices (absolute count and PLR) are prognosis predictors in LBC patients. Platelet > 279 x 103/mm3 and PRL < 191.5 was associated with a higher OS, with the PRL being an independent predictor of higher OS. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
32. Ki 67: a Promising Prognostic Marker in Early Breast Cancer—a Review Article.
- Author
-
Louis, Dhanya Mary, Nair, Lakshmi Malavika, Vallonthaiel, Archana George, Narmadha, M. P., and Vijaykumar, D. K.
- Abstract
Ki67 index is considered to be a reliable indicator of the proliferative activity of breast cancer. Additionally, the Ki67 proliferative marker may play a role in assessing response to systemic therapeutic strategies and can act as a prognostic biomarker. But its limited reproducibility which stems from a lack of standardization of procedures, inter-observer variability, and preanalytical and analytical variabilities all have hampered the use of the Ki67 index in clinical practice. Currently, clinical trials have been evaluating Ki67 as a predictive marker for needing adjuvant chemotherapy in luminal early breast cancer patients receiving neoadjuvant endocrine therapy. But the inconsistencies existing in the estimation of the Ki67 index limit the utility of Ki67 in standard clinical practice. The purpose of this review is to evaluate the benefits and drawbacks of utilizing Ki-67 in early-stage breast cancer to prognosticate the disease and predict the risk of recurrence. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
33. Cell State Transitions and Phenotypic Heterogeneity in Luminal Breast Cancer Implicating MicroRNAs as Potential Regulators.
- Author
-
Richard, Vinitha, Nair, Madhumathy G., Jaikumar, Vishnu S., Jones, Sara, Prabhu, Jyothi S., and Kerin, Michael J.
- Subjects
- *
PHENOTYPIC plasticity , *CANCER cells , *TRIPLE-negative breast cancer , *BREAST cancer , *CARRIER proteins , *CANCER stem cells , *BREAST , *EPIDERMAL growth factor receptors - Abstract
Luminal breast cancer subtypes respond poorly to endocrine and trastuzumab treatments due to cellular heterogeneity arising from the phenotype transitions, accounted for mainly by the loss of receptor expression. The origins of basal-like and human epidermal growth factor receptor 2 (HER2)-overexpressing breast cancer subtypes have been attributed to genetic and protein modifications in stem-like cells and luminal progenitor cell populations, respectively. The post-transcriptional regulation of protein expression is known to be influenced by microRNAs (miRNAs) that are deemed to be master regulators of several biological processes in breast tumorigenesis and progression. Our objective was to identify the fractions of luminal breast cancer cells that share stemness potentials and marker profiles and to elucidate the molecular regulatory mechanism that drives transitions between fractions, leading to receptor discordances. Established breast cancer cell lines of all prominent subtypes were screened for the expression of putative cancer stem cell (CSC) markers and drug transporter proteins using a side population (SP) assay. Flow-cytometry-sorted fractions of luminal cancer cells implanted in immunocompromised mice generated a pre-clinical estrogen receptor alpha (ERα+) animal model with multiple tumorigenic fractions displaying differential expression of drug transporters and hormone receptors. Despite an abundance of estrogen receptor 1 (ESR1) gene transcripts, few fractions transitioned to the triple-negative breast cancer (TNBC) phenotype with a visible loss of ER protein expression and a distinct microRNA expression profile that is reportedly enriched in breast CSCs. The translation of this study has the potential to provide novel therapeutic miRNA-based targets to counter the dreaded subtype transitions and the failure of antihormonal therapies in the luminal breast cancer subtype. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
34. Dual Function of CCAT2 in Regulating Luminal Subtype of Breast Cancer Depending on the Subcellular Distribution.
- Author
-
Xie, Heying, Guo, Yuefan, Xu, Zhen, Wang, Qiong, Wang, Tao, Gu, Yi, Li, Danni, Liu, Yu, Ma, Wenjing, Liu, Pengfei, Zhao, Qian, Lü, Jinhui, Liu, Junjun, and Yu, Zuoren
- Subjects
- *
RNA analysis , *FLOW cytometry , *SEQUENCE analysis , *ONCOGENES , *WESTERN immunoblotting , *ONE-way analysis of variance , *CANCER patients , *GENE expression , *CELLULAR signal transduction , *T-test (Statistics) , *CELL proliferation , *STEM cells , *TUMOR suppressor genes , *RESEARCH funding , *PHENOBARBITAL , *CELL lines , *BREAST tumors , *CYTOPLASM - Abstract
Simple Summary: Long non-coding RNAs have been demonstrated to play important roles in regulating tumor development and progression in breast cancer, which is tumor type dependent and cellular localization dependent. However, the regulatory mechanisms remain unclear. Herein, we found a dual function of long non-coding RNA CCAT2 in the luminal subtype of breast cancer, depending on its subcellular distribution. CCAT2 showed an overall downregulation in the tumor tissues from the luminal breast cancer patients. Cytoplasmic CCAT2 in the luminal subtype of breast cancer cell MCF-7 or T47D significantly suppressed cell proliferation and cancer cell stemness in vitro. It inhibited tumor growth in vivo, which was mediated with miR-221-p27 signaling. In contrast, nuclear overexpression of CCAT2 led to upregulation of OCT4-PG1 and the induction of cancer cell stemness. In summary, for the first time, the current study revealed a dual function of lncRNA CCAT2 as a tumor suppressor or oncogene depending upon its subcellular distribution. Breast cancer is the most common cancer in women around the world. Emerging evidence has indicated the important roles that non-coding RNAs play in regulating tumor development and progression in breast cancer. Herein, we found a dual function of long non-coding RNA (LncRNA) CCAT2 in the luminal subtype of breast cancer, depending on its subcellular distribution. CCAT2 showed an overall downregulation in the tumor tissues from luminal breast cancer patients. Transient overexpression of CCAT2 in the luminal subtype of breast cancer cell MCF-7 or T47D significantly suppressed cell proliferation in vitro and inhibited tumor growth in vivo. Gene expression analysis of cancer stem cell markers including OCT4, NANOG, h-TERT, SOX2 and KLF4; flow cytometry analysis of breast cancer stem cell population, and mammosphere formation assay demonstrated inhibition of cancer cell stemness with transient transfection of CCAT2 in which exogenous CCAT2 mainly distributed in the cytoplasm and regulated miR-221-p27 signaling via RNA sequence interaction. However, overexpression of CCAT2 in MCF-7 cells through pMX retroviral nuclear expression vector accumulated CCAT2 in the nucleus, leading to upregulation of OCT4-PG1, a pseudogene of stem gene OCT4, thereby promoting the cancer cell stemness. In conclusion, the current study, for the first time, revealed a dual function of lncRNA CCAT2 as a tumor suppressor or oncogene depending upon its subcellular distribution. It also demonstrated the regulatory mechanism of cytoplasmic CCAT2 in suppressing tumorigenesis in the luminal subtype of breast cancer. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
35. GLUL GENE KNOCKDOWN AND RESTRICTED GLUCOSE LEVEL SHOW SYNERGISTIC INHIBITORY EFFECT ON THE LUMINAL SUBTYPE BREAST CANCER MCF7 CELLS’ PROLIFERATION AND METASTASIS.
- Author
-
Zahmatkesh, Arezu Karimpur, Khalaj-Kondori, Mohammad, Hosseinpour Feizi, Mohammad Ali, and Baradaran, Behzad
- Subjects
- *
BREAST cancer , *CANCER cells , *CELL culture , *GENE expression , *GLUCOSE , *GLUTAMINE synthetase , *CELL proliferation - Abstract
The glutamine synthetase path is one of the most important metabolic pathways in luminal breast cancer cells, which plays a critical role in supplying glutamine as an intermediate in the biosynthesis of amino acids and nucleotides. On the other hand, glycolysis and its dominant substrate, glucose, are the most critical players in cancer metabolism. Accordingly, targeting these two critical paths might be more efficient in luminal-type breast cancer treatment. MCF7 cells were cultivated in media containing 4.5, 2, and 1 g/L glucose to study its effects on GLUL (Glutamate Ammonia Ligase) expression. Followingly, high and low glucose cell cultures were transfected with 220 pM of siGLUL and incubated for 48 h at 37 ºC. The cell cycle progression and apoptosis were monitored and assessed by flow cytometry. Expression of GLUL, known as glutamine synthetase, was evaluated in mRNA and protein levels by qRT-PCR and western blotting, respectively. To examine the migration and invasion capacity of studied cells exploited from wound healing assay and subsequent expression studies of glutathione-S-transferase Mu3 (GSTM3) and alfa-enolase (ENO1). Expression of GLUL significantly decreased in cells cultured at lower glucose levels compared to those at higher glucose levels. siRNA-mediated knockdown of GLUL expression in low glucose cultures significantly reduced growth, proliferation, migration, and invasion of the MCF7 cells and enhanced their apoptosis compared to the controls. Based on the results, GLUL suppression down-regulated GSTM3, a main detoxifying enzyme, and up-regulated Bax. According to the role of glycolysis as a ROS suppressor, decreased amounts of glucose could be associated with increased ROS; it can be considered an efficient involved mechanism in this study. Also, increased expression of Bax could be attributable to mTOR/AKT inhibition following GLUL repression. In conclusion, utilizing GLUL and glycolysis inhibitors might be a more effective strategy in luminal-type breast cancer therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2023
- Full Text
- View/download PDF
36. Ribociclib in newly diagnosed hepatitis B infection: A case report
- Author
-
Fabrizio Di Costanzo, Simone Carrano, Gennaro Iengo, Amedeo Cefaliello, Valentina Cossiga, Filomena Morisco, Mario Giuliano, Carmine De Angelis, and Grazia Arpino
- Subjects
Ribociclib ,hepatitis B ,luminal breast cancer ,CDK4/6 inhibitors ,tenofovir disoproxil fumarate ,Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,RC254-282 - Abstract
Breast cancer is the most frequently diagnosed cancer in women worldwide. Actually CDK4/6 inhibitor Ribociclib is approved for the treatment of metastatic hormone-positive and human epidermal growth factor receptor 2 (HER 2)-negative breast cancer, but comorbidities like infectious or cardiovascular diseases may limit its use.Case reportA 45-year-old woman was diagnosed with metastatic breast cancer in September 2021; also, her hepatitis screening resulted positive for hepatitis B infection. Patient assumed eradicative therapy for hepatitis and bit after started oncological therapy with Ribociclib.OutcomeFrequent check of hepatological function was observed since start of eradicative therapy; liver transaminases and bilirubin kept to not rise despite start of oncological treatment with Ribociclib. Patient’s Performance Status was also not compromised and revaluation at 4, 9 and 13 months showed partial response and then stable disease.Discussionhepatotoxicity of Ribociclib is reported as a possible side effect, and often positivity for hepatitis is cause of exclusion from therapy; in our case, no hepatotoxicity was noted and patient obtained response in terms of control of both infectious and oncological diseases.
- Published
- 2023
- Full Text
- View/download PDF
37. CNVs in 8q24.3 do not influence gene co-expression in breast cancer subtypes
- Author
-
Candelario Hernández-Gómez, Enrique Hernández-Lemus, and Jesús Espinal-Enríquez
- Subjects
gene co-expression networks ,breast cancer subtypes ,copy number variations ,conditional mutual information ,luminal breast cancer ,HER2+ breast cancer ,Genetics ,QH426-470 - Abstract
Gene co-expression networks are a useful tool in the study of interactions that have allowed the visualization and quantification of diverse phenomena, including the loss of co-expression over long distances in cancerous samples. This characteristic, which could be considered fundamental to cancer, has been widely reported in various types of tumors. Since copy number variations (CNVs) have previously been identified as causing multiple genetic diseases, and gene expression is linked to them, they have often been mentioned as a probable cause of loss of co-expression in cancerous networks. In order to carry out a comparative study of the validity of this statement, we took 477 protein-coding genes from chromosome 8, and the CNVs of 101 genes, also protein-coding, belonging to the 8q24.3 region, a cytoband that is particularly active in the appearance of breast cancer. We created CNVS-conditioned co-expression networks of each of the 101 genes in the 8q24.3 region using conditional mutual information. The study was carried out using the four molecular subtypes of breast cancer (Luminal A, Luminal B, Her2, and Basal), as well as a case corresponding to healthy samples. We observed that in all cancer cases, the measurement of the Kolmogorov-Smirnov statistic shows that there are no significant differences between one and other values of the CNVs for any case. Furthermore, the co-expression interactions are stronger in all cancer subtypes than in the control networks. However, the control network presents a homogeneously distributed set of co-expression interactions, while for cancer networks, the highest interactions are more confined to specific cytobands, in particular 8q24.3 and 8p21.3. With this approach, we demonstrate that despite copy number alterations in the 8q24 region being a common trait in breast cancer, the loss of long-distance co-expression in breast cancer is not determined by CNVs.
- Published
- 2023
- Full Text
- View/download PDF
38. Identification of circRNA-miRNA-mRNA network in luminal breast cancers by integrated analysis of microarray datasets
- Author
-
Yixiang Huang, Mingping Qian, Juhang Chu, Lei Chen, Wei Jian, and Gang Wang
- Subjects
network ,luminal breast cancer ,circRNA ,tamoxifen resistance ,hsa_circ_0086735-miR-1296-5p-STAT1 ,Biology (General) ,QH301-705.5 - Abstract
Introduction: Circular RNAs (circRNAs) regulatory network is important in human cancer. We, therefore, mapped the regulatory networks driven by circRNA in luminal-subtype breast cancer.Methods: Breast cancer-related microarray datasets from GEO database were analyzed for the differentially expressed circRNAs, miRNAs, and mRNAs. The potential downstream RNAs were collected using Circular RNA Interactome or Targetscan database. Protein-protein interaction (PPI) analysis was performed for the filtered genes to identify hub genes. The functions were annotated by the Gene Ontology (GO) and Kyoto Encyclopedia of Genes and Genomes (KEGG) enrichment analysis. CircRNA-miRNA-mRNA networks were mapped using Cytoscape software. Hsa_circ_0086735-miR-1296-5p-STAT1 axis was used for verification. The expression levels of hsa_circ_0086735, miR-1296-5p, and STAT1 mRNA were confirmed by qRT-PCR in luminal-subtype tissues and cell lines. The interactions among them were verified by Luciferase reporter assay and RNA pull-down assay. Cell proliferation and apoptosis were assayed. Overall and distant metastasis-free survival was analyzed.Results: A total of 70 genes were finally targeted and enriched in multi-process and multi-pathway. Networks containing 96 circRNA-miRNA-mRNA axes were constructed. Hsa_circ_0086735 and STAT1 mRNA was upregulated in luminal breast cancer, while miR-1296-5p was downregulated. Hsa_circ_0086735-miR-1296-5p-STAT1 axis promotes breast cancer progression and contributes to tamoxifen resistance. High hsa_circ_0086735 was associated with poor overall and distant metastasis-free survival.Discussion: This study identified the hsa_circ_0086735-miR-1296-5p-STAT1 as an important regulatory axis in luminal-subtype breast cancer, aiding to determine potential therapeutic targets.
- Published
- 2023
- Full Text
- View/download PDF
39. Association of SLC12A1 and GLUR4 Ion Transporters with Neoadjuvant Chemoresistance in Luminal Locally Advanced Breast Cancer
- Author
-
Montserrat Justo-Garrido, Alejandro López-Saavedra, Nicolás Alcaraz, Carlo C. Cortés-González, Luis F. Oñate-Ocaña, Claudia Haydee Sarai Caro-Sánchez, Clementina Castro-Hernández, Cristian Arriaga-Canon, José Díaz-Chávez, and Luis A. Herrera
- Subjects
luminal breast cancer ,locally advanced ,chemoresistance ,neoadjuvant chemotherapy ,ion transport ,Biology (General) ,QH301-705.5 ,Chemistry ,QD1-999 - Abstract
Chemoresistance to standard neoadjuvant treatment commonly occurs in locally advanced breast cancer, particularly in the luminal subtype, which is hormone receptor-positive and represents the most common subtype of breast cancer associated with the worst outcomes. Identifying the genes associated with chemoresistance is crucial for understanding the underlying mechanisms and discovering effective treatments. In this study, we aimed to identify genes linked to neoadjuvant chemotherapy resistance in 62 retrospectively included patients with luminal breast cancer. Whole RNA sequencing of 12 patient biopsies revealed 269 differentially expressed genes in chemoresistant patients. We further validated eight highly correlated genes associated with resistance. Among these, solute carrier family 12 member 1 (SLC12A1) and glutamate ionotropic AMPA type subunit 4 (GRIA4), both implicated in ion transport, showed the strongest association with chemoresistance. Notably, SLC12A1 expression was downregulated, while protein levels of glutamate receptor 4 (GLUR4), encoded by GRIA4, were elevated in patients with a worse prognosis. Our results suggest a potential link between SLC12A1 gene expression and GLUR4 protein levels with chemoresistance in luminal breast cancer. In particular, GLUR4 protein could serve as a potential target for drug intervention to overcome chemoresistance.
- Published
- 2023
- Full Text
- View/download PDF
40. Alpha-smooth muscle actin-positive cancer-associated fibroblasts secreting osteopontin promote growth of luminal breast cancer
- Author
-
Anna Muchlińska, Anna Nagel, Marta Popęda, Jolanta Szade, Magdalena Niemira, Jacek Zieliński, Jarosław Skokowski, Natalia Bednarz-Knoll, and Anna J. Żaczek
- Subjects
Cancer-associated fibroblast ,Luminal breast cancer ,Alpha-smooth muscle actin ,Osteopontin ,Cytology ,QH573-671 - Abstract
Abstract Background Cancer-associated fibroblasts (CAFs) have been shown to support tumor development in a variety of cancers. Different markers were applied to classify CAFs in order to elucidate their impact on tumor progression. However, the exact mechanism by which CAFs enhance cancer development and metastasis is yet unknown. Methods Alpha-smooth muscle actin (α-SMA) was examined immunohistochemically in intratumoral CAFs of nonmetastatic breast cancers and correlated with clinicopathological data. Four CAF cell lines were isolated from patients with luminal breast cancer (lumBC) and classified according to the presence of α-SMA protein. Conditioned medium (CM) from CAF cultures was used to assess the influence of CAFs on lumBC cell lines: MCF7 and T47D cells using Matrigel 3D culture assay. To identify potential factors accounting for promotion of tumor growth by α-SMAhigh CAFs, nCounter PanCancer Immune Profiling Panel (NanoString) was used. Results In luminal breast cancer, presence of intratumoral CAFs expressing high level of α-SMA (13% of lumBC group) correlated with poor prognosis (p = 0.019). In in vitro conditions, conditioned medium obtained from primary cultures of α-SMA-positive CAFs isolated from luminal tumors was observed to enhance growth of lumBC cell line colonies in 3D Matrigel, in contrast to CM derived from α-SMA-negative CAFs. Multigene expression analysis indicated that osteopontin (OPN) was overexpressed in α-SMA-positive CAFs in both clinical samples and in vitro models. OPN expression was associated with higher percentage of Ki67-positive cells in clinical material (p = 0.012), while OPN blocking in α-SMA-positive CAF-derived CM attenuated growth of lumBC cell line colonies in 3D Matrigel. Conclusions Our findings demonstrate that α-SMA-positive CAFs might enhance tumor growth via secretion of OPN.
- Published
- 2022
- Full Text
- View/download PDF
41. Alpelisib therapy: from theory to practice
- Author
-
E. V. Lubennikova, T. A. Titova, and I. P. Ganshina
- Subjects
pik3ca mutation ,alpelisib ,fulvestrant ,metastatic breast cancer ,luminal breast cancer ,endocrine therapy ,endocrine resistance ,Medicine - Abstract
Before the development and implementation of the first PI3K inhibitor (alpelisib), the presence of a mutation in the PIK3CA gene had only prognostic value: it determined the unfavorable course of luminal HER2-negative metastatic breast cancer (testing for mutations was not part of routine screening methods). Achievements in the treatment of HR+HER2- mBC are primarily associated with the use of CDK4/6 inhibitors, which allowed not only a significant increase in the median progression-free survival while maintaining high quality of life, but also significantly increased overall survival of patients with luminal HER2-negative metastatic breast cancer. However, subgroup analyses demonstrate that the presence of the PIK3CA mutation is an independent factor in decreasing progression-free time and overall survival, even in patients treated with CDK4/6 inhibitors. Mutations of the PIK3CA gene are diagnosed in 30-40% of luminal metastatic breast cancer patients, they are associated with an increased risk of relapse and disease progression, are associated with a significant reduction in survival rates and treatment effectiveness, and determine the development of primary and secondary resistance to endocrine therapy. Standard endocrine therapy with fulvestrant combined with alpelisib has significantly improved treatment outcomes in patients with HR+HER2-metastatic breast cancer with the PIK3CA mutation who previously received treatment for advanced disease or had progression during adjuvant therapy. This combination is now included in all major international guidelines and is a priority therapy option. Testing for PIK3CA mutations is the current diagnostic standard in luminal HER2-negative mBC. The review presents an update of the main clinical trials with alpelisib, treatment results from real clinical practice, and also considers aspects of use in pretreated patients with different medical history. The article outlines the main recommendations for the prevention and correction of adverse events, and presents our own experience of using alpelisib in a patient with a classic course of breast cancer with a PIK3CA mutation.
- Published
- 2022
- Full Text
- View/download PDF
42. ECM1 is associated with endocrine resistance in ER+ breast cancers
- Author
-
Tae Won Lee and Kyung-min Lee
- Subjects
ECM1 ,ER+ breast cancer ,endocrine resistance ,luminal breast cancer ,Src ,Medicine (General) ,R5-920 ,Biology (General) ,QH301-705.5 - Abstract
Extracellular matrix protein 1 (ECM1) is associated with a poor prognosis of breast cancers. However, the role of ECM1 with endocrine resistance in estrogen receptor-positive (ER+) breast cancers has not been elucidated yet. We show that ECM1 promotes endocrine resistance in ER+ breast cancers. ECM1 is overexpressed in luminal breast cancer patients compared to the basal type of breast cancer. Significantly, higher expression of ECM1 is associated with poor response to endocrine therapies in luminal B breast cancer patients. We found that ECM1 is upregulated in CAMA1 and MDA-MB-361 cells grown in long-term estrogen-deprived (LTED) conditions. Moreover, the ablation of ECM1 significantly inhibited the proliferation of CAMA1 LTED and MDA-MB-361 LTED cells. Finally, an interrogation of a dataset containing transcriptome and proteome of breast cancer cell lines revealed that the level of ECM1 mRNA is positively correlated with that of phosphorylated Src. Based on these findings, we strongly suggest that ECM1 significantly contributes to the acquisition of endocrine resistance in ER+ breast cancers by the activation of Src.
- Published
- 2022
- Full Text
- View/download PDF
43. Challenging Endocrine Sensitivity of Hormone Receptor-Positive/HER2-Negative Advanced Breast Cancer with the Combination of Eribulin and Endocrine Therapy: The REVERT Study.
- Author
-
López González, Ana, Del Barco Berrón, Sonia, Grau, Isabel, Galan, Maria, Castelo Fernández, Beatriz, Cortés, Alfonso, Sánchez Rovira, Pedro, Martinez-Bueno, Alejandro, Gonzalez, Xavier, García, Almudena, Gener, Petra, Mina, Leonardo, Alcalá-López, Daniel, Sampayo, Miguel, Cortés, Javier, Pérez-Garcia, José Manuel, Llombart-Cussac, Antonio, and López-Miranda, Elena
- Subjects
- *
DRUG efficacy , *CONFIDENCE intervals , *ONCOGENES , *ANTINEOPLASTIC agents , *IMMUNOMODULATORS , *RANDOMIZED controlled trials , *TREATMENT effectiveness , *ERIBULIN , *AROMATASE inhibitors , *SENSITIVITY & specificity (Statistics) , *BREAST tumors , *DRUG resistance in cancer cells , *PHARMACODYNAMICS - Abstract
Simple Summary: Acquiring of resistance is a common outcome after prolonged cancer treatment and consecutive treatments are, in general terms, limited. Here we published the results of REVERT clinical study that aimed to REVERT the resistance to hormonal treatment that often occurs in breast cancer patients positive for hormone receptors. According to previous published data, adding drug called eribulin to hormonal treatment may sensitized the tumor to the hormonal treatment due to switch of cancer cell phenotype. Even though this theory was not proved in this study, the outcomes of this study open a new door for further investigation since the results suggests that the patients treated with hormonal therapy and inhibitors of cyclins may have further clinical benefit, if eribulin is added to the therapy. Importantly, no additional unexpected side effects were reported with this drug combination. Background: Luminal advanced breast cancer (ABC) patients eventually progress on endocrine therapy. REVERT aimed to explore whether eribulin could restore endocrine sensitivity in a randomized, non-comparative phase II trial. Methods: Aromatase inhibitor (AI)-resistant patients with luminal ABC were randomized 1:1 to receive eribulin +/− AI. Patients were stratified by prior cyclin-dependent kinases 4/6 inhibitor (CDK4/6i) treatment. The primary endpoint was an investigator-assessed overall response rate (ORR) according to RECIST version 1.1 in the eribulin + AI arm. An interim analysis was planned with 11 evaluable patients according to a two-stage Simon design. Results: Twenty-two patients were enrolled (15 eribulin + AI arm; 7 eribulin arm). The trial was terminated early in March 2021, with eight (36.4%) patients still on treatment. ORR was 26.7% in the eribulin + AI arm (95% CI, 7.8–55.1%; p = 0.0541). In the eribulin arm, two (28.6%) patients had an objective response (95% CI, 3.7–71.0%). The difference between the study arms was not significant (p = 0.918). The addition of AI to eribulin also failed to show improvement in other efficacy endpoints. A significant interaction between the treatment arm and previous CDK4/6i treatment was observed for ORR (p = 0.018) and progression-free survival (p = 0.084). Overall, the toxicity profile was consistent with the known safety profile of eribulin. No treatment-related deaths were reported. Conclusion: Eribulin + AI does not seem to improve outcomes compared with eribulin monotherapy in patients with AI-resistant luminal ABC. This chemo–endocrine approach deserves further investigation after progression to CDK4/6i-based therapy. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
44. The Bio-Diversity and the Role of Gut Microbiota in Postmenopausal Women with Luminal Breast Cancer Treated with Aromatase Inhibitors: An Observational Cohort Study.
- Author
-
Lasagna, Angioletta, De Amici, Mara, Rossi, Chiara, Zuccaro, Valentina, Corbella, Marta, Petazzoni, Greta, Comandatore, Francesco, Sacchi, Lucia, Testa, Giorgia, Ferraris, Elisa, Rizzo, Gianpiero, Tancredi, Richard, Ferrari, Alessandra, Lucioni, Marco, Sacchi, Paolo, Bruno, Raffaele, and Pedrazzoli, Paolo
- Subjects
AROMATASE inhibitors ,BREAST cancer ,GUT microbiome ,POSTMENOPAUSE ,SCIENTIFIC observation ,COHORT analysis - Abstract
The interactions between aromatase inhibitors (AI) in breast cancer (BC) and gut microbiota (GM) have not been completely established yet. The aim of the study is to evaluate the bio-diversity of GM and the relationship between GM, inflammation and tumor-infiltrating lymphocytes (TILs) in postmenopausal women with BC during adjuvant AI treatment compared to women with disease relapse during or after one year of AI therapy ("endocrine-resistant"). We conducted a monocenter observational case-control study. Eighty-four women with BC (8 cases, 76 controls) were enrolled from 2019 to 2021. We observed a significant difference in the mean microbial abundance between the two groups for the taxonomic rank of order (p 0.035) and family (p 0.029); specifically, the case group showed higher diversity than the control group. Veillonella reached its maximum abundance in cases (p 0.022). Cytokine levels were compared among the groups created considering the TILs levels. We obtained a statistically significant difference (p 0.045) in IL-17 levels among the groups, with patients with low TILs levels showing a higher median value for IL-17 (0.15 vs. 0.08 pg/mL). Further studies about the bio-diversity in women with BC may lead to the development of new biomarkers and targeted interventions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
45. Classification of Subgroups with Immune Characteristics Based on DNA Methylation in Luminal Breast Cancer.
- Author
-
Zhang, Mengyan, Ma, Te, Wang, Cong, Zhao, Jiyun, Xing, Jie, Liu, Honghao, Su, Mu, Zhai, Ruiyang, Liu, Ting, Sun, Baoqing, and Zhang, Yan
- Subjects
- *
DNA methylation , *BREAST cancer , *IMMUNE checkpoint proteins , *FEATURE selection , *TUMOR-infiltrating immune cells , *METHYLATION , *HISTONE methylation - Abstract
Luminal breast cancer (BC) accounts for a large proportion of patients in BC, with high heterogeneity. Determining the precise subtype and optimal selection of treatment options for luminal BC is a challenge. In this study, we proposed an MSBR framework that integrate DNA methylation profiles and transcriptomes to identify immune subgroups of luminal BC. MSBR was implemented both on a key module scoring algorithm and "Boruta" feature selection method by DNA methylation. Luminal A was divided into two subgroups and luminal B was divided into three subgroups using the MSBR. Furthermore, these subgroups were defined as different immune subgroups in luminal A and B respectively. The subgroups showed significant differences in DNA methylation levels, immune microenvironment (immune cell infiltration, immune checkpoint PD1/PD-L1 expression, immune cell cracking activity (CYT)) and pathology features (texture, eccentricity, intensity and tumor-infiltrating lymphocytes (TILs)). The results also showed that there is a subgroup in both luminal A and B that has the benefit from immunotherapy. This study proposed a classification of luminal BC from the perspective of epigenetics and immune characteristics, which provided individualized treatment decisions. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
46. Type IV collagen α5 chain promotes luminal breast cancer progression through c-Myc-driven glycolysis.
- Author
-
Wu, Yuexin, Liu, Xiangming, Zhu, Yue, Qiao, Yuemei, Gao, Yuan, Chen, Jianfeng, and Ge, Gaoxiang
- Abstract
Cancer cell metabolism reprogramming is one of the hallmarks of cancer. Cancer cells preferentially utilize aerobic glycolysis, which is regulated by activated oncogenes and the tumor microenvironment. Extracellular matrix (ECM) in the tumor microenvironment, including the basement membranes (BMs), is dynamically remodeled. However, whether and how ECM regulates tumor glycolysis is largely unknown. We show that type IV collagens, components of BMs essential for the tissue integrity and proper function, are differentially expressed in breast cancer subtypes that α5 chain (α5(IV)) is preferentially expressed in the luminal-type breast cancer and is regulated by estrogen receptor-α. α5(IV) is indispensable for luminal breast cancer development. Ablation of α5(IV) significantly reduces the growth of luminal-type breast cancer cells and impedes the development of luminal-type breast cancer. Impaired cell growth and tumor development capability of α5(IV)-ablated luminal breast cancer cells is attributed to the reduced expression of glucose transporter and glycolytic enzymes and impaired glycolysis in luminal breast cancer cells. Non-integrin collagen receptor discoidin domain receptor-1 (DDR1) expression and p38 mitogen-activated protein kinase activation are attenuated in α5(IV)-ablated luminal breast cancer cells, resulting in reduced c-Myc oncogene expression and phosphorylation. Ectopic expression of constitutively active DDR1 or c-Myc restores the expression of glucose transporter and glycolytic enzymes, and thereafter restores aerobic glycolysis, cell proliferation, and tumor growth of luminal breast cancer. Thus, type IV collagen α5 chain is a luminal-type breast cancer-specific microenvironmental regulator modulating cancer cell metabolism. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
47. Contribution of BRCA1 5382insC mutation to triplene-gative and luminal types of breast cancer in Ukraine.
- Author
-
Samusieva, Anastasiia, Serga, Svitlana, Klymenko, Sergiy, Rybchenko, Lyudmila, Klimuk, Bohdana, Zakhartseva, Liubov, Gorovenko, Natalia, Lobanova, Olga, Rossokha, Zoia, Fishchuk, Liliia, Levkovich, Nataliia, Medvedieva, Nataliia, Popova, Olena, Cheshuk, Valeriy, Inomistova, Mariia, Khranovska, Natalia, Skachkova, Oksana, Michailovich, Yurii, Ponomarova, Olga, and Kozeretska, Iryna
- Abstract
Purpose: The gene BRCA1 plays a key role in DNA repair in breast and ovarian cell lines and this is considered one of target tumor suppressor genes in same line of cancers. The 5382insC mutation is among the most frequently detected in patients (Eastern Europe) with triple-negative breast cancer (TNBC). In Ukraine, there is not enough awareness of necessity to test patients with TNBC for BRCA1 mutations. That is why this group of patients is not well-studied, even through is known the mutation may affect the course of disease. Methods: The biological samples of 408 female patients were analyzed of the 5382insC mutation in BRCA1. We compared the frequency of the 5382insC mutation in BRCA1 gene observed in Ukraine with known frequencies in other countries. Results: For patients with TNBC, BRCA1 mutations frequency was 11.3%, while in patients with luminal types of breast cancers, the frequency was 2.8%. Prevalence of 5382insC among TNBC patients reported in this study was not different from those in Tunisia, Poland, Russia, and Bulgaria, but was higher than in Australia and Germany. Conclusion: The BRCA1 c.5382 mutation rate was recorded for the first time for TNBC patients in a Ukrainian population. The results presented in this study underscore the importance of this genetic testing of mutations in patients with TNBC. Our study supports BRCA1/2 genetic testing for all women diagnosed with TNBC, regardless of the age of onset or family history of cancer and not only for women diagnosed with TNBC at <60y.o., as guidelines recommend. [ABSTRACT FROM AUTHOR]
- Published
- 2022
- Full Text
- View/download PDF
48. L1-Regularized Neural Ranking for Risk Stratification and Its Application to Prediction of Time to Distant Metastasis in Luminal Node Negative Chemotherapy Naïve Breast Cancer Patients
- Author
-
Minhas, Fayyaz, Toss, Michael S., ul Wahab, Noor, Rakha, Emad, Rajpoot, Nasir M., Filipe, Joaquim, Editorial Board Member, Ghosh, Ashish, Editorial Board Member, Prates, Raquel Oliveira, Editorial Board Member, Zhou, Lizhu, Editorial Board Member, Kamp, Michael, editor, Koprinska, Irena, editor, Bibal, Adrien, editor, Bouadi, Tassadit, editor, Frénay, Benoît, editor, Galárraga, Luis, editor, Oramas, José, editor, Adilova, Linara, editor, Krishnamurthy, Yamuna, editor, Kang, Bo, editor, Largeron, Christine, editor, Lijffijt, Jefrey, editor, Viard, Tiphaine, editor, Welke, Pascal, editor, Ruocco, Massimiliano, editor, Aune, Erlend, editor, Gallicchio, Claudio, editor, Schiele, Gregor, editor, Pernkopf, Franz, editor, Blott, Michaela, editor, Fröning, Holger, editor, Schindler, Günther, editor, Guidotti, Riccardo, editor, Monreale, Anna, editor, Rinzivillo, Salvatore, editor, Biecek, Przemyslaw, editor, Ntoutsi, Eirini, editor, Pechenizkiy, Mykola, editor, Rosenhahn, Bodo, editor, Buckley, Christopher, editor, Cialfi, Daniela, editor, Lanillos, Pablo, editor, Ramstead, Maxwell, editor, Verbelen, Tim, editor, Ferreira, Pedro M., editor, Andresini, Giuseppina, editor, Malerba, Donato, editor, Medeiros, Ibéria, editor, Fournier-Viger, Philippe, editor, Nawaz, M. Saqib, editor, Ventura, Sebastian, editor, Sun, Meng, editor, Zhou, Min, editor, Bitetta, Valerio, editor, Bordino, Ilaria, editor, Ferretti, Andrea, editor, Gullo, Francesco, editor, Ponti, Giovanni, editor, Severini, Lorenzo, editor, Ribeiro, Rita, editor, Gama, João, editor, Gavaldà, Ricard, editor, Cooper, Lee, editor, Ghazaleh, Naghmeh, editor, Richiardi, Jonas, editor, Roqueiro, Damian, editor, Saldana Miranda, Diego, editor, Sechidis, Konstantinos, editor, and Graça, Guilherme, editor
- Published
- 2021
- Full Text
- View/download PDF
49. p53 Mutation as Plausible Predictor for Endocrine Resistance Therapy in Luminal Breast Cancer [version 2; peer review: 2 approved]
- Author
-
Freda Halim, Yohana Azhar, Suwarman Suwarman, and Bethy Hernowo
- Subjects
Review ,Articles ,p53 ,predictor ,endocrine therapy resistance ,luminal breast cancer - Abstract
Endocrine therapy resistance in Luminal Breast Cancer is a significant issue to be tackled, but currently, no specific biomarker could be used to anticipate this event. p53 mutation is widely known as one of Breast Cancer’s most prominent genetic alterations. Its mutation could generate various effects in Estrogen Receptor and Progesterone Receptor molecular works, tangled in events leading to the aggravation of endocrine therapy resistance. Hence the possibility of p53 mutation utilization as an endocrine therapy resistance predictive biomarker is plausible. The purpose of this review is to explore the latest knowledge of p53 role in Estrogen Receptor and Progesterone Receptor molecular actions, thus aggravating the Endocrine Therapy resistance in Luminal Breast Cancer, from which we could define possibilities and limitations to utilize p53 as the predictive biomarker of endocrine therapy resistance in Luminal Breast Cancer.
- Published
- 2022
- Full Text
- View/download PDF
50. Clinical case of the treatment of metastatic luminal breast cancer
- Author
-
A. F. Nasretdinov, A. V. Sultanbaev, K. V. Menshikov, Sh. I. Musin, N. I. Sultanbaeva, A. A. Izmailov, and R. T. Ayupov
- Subjects
clinical case ,luminal breast cancer ,cdk 4/6 inhibitors ,ribociclib ,cytomegalovirus keratitis ,Medicine - Abstract
Hormone therapy currently open up the prospect of long-term, comfortable and relatively low-toxic treatment for patients with hormone receptor – positive advanced breast cancer. For a long time, the presence of visceral metastases prompted oncologists to abandon hormone therapy in favor of cytostatic agents. Now days, even in the presence of visceral metastases, clinical guidelines allow use of modern hormonal therapy in the absence of a visceral crisis. In particular, the so-called CDK 4/6 inhibitors, presented on the Russian market by drugs: palbociclib, ribociclib and abemacyclib, became the drugs that significantly improved the results of hormone therapy. Each of them has demonstrated its effectiveness in clinical trials; moreover, there are lots of clinical cases demonstrating the benefits of this therapy in real clinical practice. The article presents a clinical case of treatment of advanced hormone receptor-positive breast cancer. The effectiveness of treatment with CDK 4/6 inhibitors has been demonstrated, a comparatively analysed with the data obtained in the course of clinical trials. The analysis of the tactics of treatment of cytomegalovirus infection of the cornea during therapy with ribociclib was carried out.
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.